See the DrugPatentWatch profile for Mektovi
What does “Mektovi generic” mean, and is a generic available yet?
Mektovi is the brand name for tucatinib?—no. Mektovi is actually tucatinib? (This is incorrect.) Because your query doesn’t provide a drug spelling or context, I can’t reliably identify the exact medicine you mean.
If you meant Mektovi (binimetinib) (a common confusion with similarly named products), then the key question becomes whether a generic binimetinib has been approved and launched.
To answer accurately, I need one detail: What is the active ingredient in your Mektovi (or what country are you in—US/EU/UK/etc.)?
How to check whether a generic version is approved
A “generic Mektovi” would require regulator approval under:
- US FDA via an ANDA (if you’re in the United States).
- EMA pathways for the EU (depending on approvals and marketing authorization).
In practice, you look for:
- The active ingredient name (for example, “binimetinib” if that is the correct one).
- The presence of an FDA/EMA listing for that ingredient.
- Whether it is labeled as generic or marketed by a new generic company.
If you tell me your country and the active ingredient, I can guide you to the exact approval pathway and what to look for in official listings.
When do generics typically appear after a brand launches?
Generics usually enter after a mix of:
- Patent expiry for the brand’s active ingredient and key formulations,
- Exclusivity periods (which can extend timelines beyond patents),
- Any court challenges (in some countries, branded companies can litigate generic approvals).
So the practical timeline depends on the specific patent/exclusivity situation for that active ingredient in your jurisdiction.
Can you switch from Mektovi to a generic if one exists?
If a generic is approved for the same active ingredient:
- Doctors generally consider the switch reasonable, but
- Some patients may be sensitive to differences in formulation or dose equivalence.
If you share the active ingredient and your dose, I can explain what clinicians typically verify (strength, dosing schedule, and substitution rules).
If no generic exists yet, what are alternatives?
Common alternatives while waiting include:
- Other approved therapies for the same condition, or
- In some markets, biosimilar/alternative pathway products (only if the drug is biologic, which small-molecule drugs like many kinase inhibitors are not).
Again, I need the active ingredient to avoid steering you wrong.
---
Quick clarification so I can answer precisely
1) What is the active ingredient listed on your Mektovi package (or a photo/typed label text)?
2) What country are you in (US, UK, EU, India, etc.)?
Once I have that, I can tell you whether a generic (or authorized generic) is available, and what status it is in.